Alterations in Brain High-Energy Phosphate and Membrane Phospholipid Metabolism in First-Episode, Drug-Naive Schizophrenics: A Pilot Study of the Dorsal Prefrontal Cortex by In Vivo Phosphorus 31 Nuclear Magnetic Resonance Spectroscopy

Archives of General Psychiatry

Volumn 48, Issue 6, 1991, Pages 563-568

  Pettegrew, Jay W ^a   Keshavan, Matcheri S ^a   Panchalingam, Kanagasabai ^a   Strychor, Sandra ^a   Kaplan, David B ^a   Tretta, Marjorie G ^a   Allen, Maureen ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PHOSPHATE; PHOSPHODIESTER; PHOSPHOMONOESTER; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; FEMALE; FRONTAL LOBE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGE FACTORS; BRAIN; EDUCATIONAL STATUS; FEMALE; FRONTAL LOBE; HUMAN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHORUS; PILOT PROJECTS; SCHIZOPHRENIA; SEX FACTORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025769846     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1991.01810300075011     Document Type: Article

References (61)

1. Zec RF, Weinberger DR. Brain areas implicated in schizophrenia: a selective review. In: Nasrallah HA, Weinberger DR, eds. Handbook of Neurology. New York, NY: Elsevier Science Publishing Co Inc; 1986;1(The Neurology ofSchizophrenia):175-206.
2. Kraepelin E. Dementia Praecox and Paraphrenia. New York, NY: Robert E Krieger Publishing Co Inc; 1919.
3. Davison K, Bagley CR. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: a review of the literature. In: Harrington RN, ed. Current Problems in Neuropsychiatry, Schizophrenia, Epilepsy, the Temporal Lobe. Ashford, England: Headly Brothers; 1969:113-189. British Journal of Psychiatry Special Publication 4.
4. Parfitt DN. The neurology of schizophrenia. J Ment Sci. 1956;102:671.
5. Buchsbaum MS, Ingvar DH, Kessler R, Waters RN, Cappelette J, van Kammen DP, King C Johnson JL, Manning RB, Flynn RW, Mann LS, Bunney WE, Sokoloff L. Cerebral glucography with positron tomography. Arch Gen Psychiatry. 1982;39:251-259.
6. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43:114-124.
7. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 1974;50:425-462.
8. Berman KF, Illowsky BP, Weinberger DR. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, IV: further evidence for regional and behavioral specificity. Arch Gen Psychiatry. 1988;45:616-622.
9. Buchsbaum MS. Position emission tomography in schizophrenia. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:783-792.
10. Essali MA, Das I, deBelleroche J, Hirsh SR. The platelet polyphosphoinositide system in schizophrenia: pathological and pharmacological implications. Schizophr Res. 1989;2:148.
11. Pettegrew JW, Kopp SJ, Dadok J, Minshew NJ, Feliksik JM, Glonek T, Cohen MM. Chemical characterization of a prominent phosphomonoester resonance from mammalian brain: P and H NMR analysis at 4.7 and 14.1 tesla. J Magn Reson. 1986;67:443-450.
12. Pettegrew JW, Kopp SJ, Minshew NJ, Glonek T, Feliksik JM, Tow JP, Cohen MM. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: preliminary observations. J Neuropathol Exp Neurol. 1987;46:419-430.
13. Pettegrew JW, Withers G, Panchalingam K, Post JFM. 31P nuclear magnetic resonance (NMR) spectroscopy of brain in aging and Alzheimer's disease. J Neurotrans. 1987;24:261-268.
14. Petroff OAC, Prichard JW, Behar KL, Alger JR, den Hollander JA, Shulman RG. Cerebral intracellular pH by 31P nuclear magnetic resonance spectroscopy. Neurology. 1985;35:781-788.
15. Pettegrew JW, Withers G, Panchalingam K, Post JFM. Considerations for brain pH assessment by P NMR. Magn Reson Imaging. 1988;6:135-142.
16. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978;35:837-844.
17. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
18. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC) for a Selected Group of Function Disorders. 3rd ed. New York, NY: New York State Psychiatric Institute; 1978.
19. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
20. Bendall MR, Pegg DT. Depth, polarization transfer and sample localization combined using surface coils. J Magn Reson. 1984;57:337-343.
21. Bendall MR, Pegg DT. Theoretical description of depth pulse sequences on and off resonance including improvements and extensions thereof. Magn Reson Med. 1985;2:91-113.
22. Bendall MR. Surface coil techniques for in vivo NMR. Bull Magn Reson. 1986;8:17-44.
23. Bendall MR. Theory and techniques of surface coils in vivo spectroscopy. In: Pettegrew JW, ed. NMR: Principles and Applications to Biomedical Research. New York, NY: Springer-Verlag NY Inc; 1990:401-428.
24. Pettegrew JW, Minshew NJ, Diehl J, Smith T, Kopp SJ, Glonek T. Anatomical considerations for interpreting topical P-NMR. Lancet. 1983;2:913. Letter.
25. Glonek T, Kopp SJ, Kot E, Pettegrew JW, Harrison WH, Cohen M. P-31 nuclear magnetic resonance analysis of brain: the perchloric acid extract spectrum. J Neurochem. 1982;39:1210-1219.
26. Cohen MM, Pettegrew JW, Kopp SJ, Minshew N, Glonek T. P-31 nuclear magnetic resonance analysis of brain: normoxic and anoxic brain slices. Neurochem Res. 1984;9:785-801.
27. Pettegrew JW, Panchalingam K, Withers G, McKeag D, Strychor S. Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat. J Neuropathol Exp Neurol. 1990;49:237-249.
28. Panchalingam K, Post JFM, Pettegrew JW. Evidence for increased aluminum binding ligands in Alzheimer's disease: a P NMR study. Neurology. 1987;37(suppl 1):331. Abstract.
29. Pettegrew JW. Molecular insights into Alzheimer's disease. Ann NY Acad Sci. 1989;568:5-38.
30. McIlwain H, Bachelard HS. Biochemistry and the Central Nervous System. New York, NY: Churchill Livingstone Inc; 1985.
31. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 1984;312:315-321.
32. Majerus PW, Connolly TM, Deckmyn H, Ross TS, Bross TE, Ishii H, Bansal VS, Wilson DB. The metabolism of phosphoinositide-derived messenger molecules. Science. 1986;234:1519-1526.
33. Gattaz W. Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987;22:421-426.
34. Pettegrew JW, Minshew NJ, Cohen MM, Kopp SJ, Glonek T. 31P NMR changes in Alzheimer's and Huntington's disease brain. Neurology. 1984;34(suppl 1):281. Abstract.
35. Pettegrew JW, Moossy J, Withers G, McKeag D, Panchalingam K. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol. 1988;47:235-248.
36. Pettegrew JW, Panchalingam K, Moossy J, Martinez J, Rao G, Boller F. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphological findings in Alzheimer's disease. Arch Neurol. 1988;45:1093-1096.
37. Brown GG, Levine SR, Gorell JM, Pettegrew JW, Gdowski JW, Bueri JA, Helpern JS, Welch KMA. In vivo P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology. 1989;39:1423-1427.
38. Minshew NJ, Pettegrew JW, Payton JB, Panchalingam K. Metabolic alterations in the dorsal prefrontal cortex of autistic patients with normal IQ. Ann Neurol. 1989;26:438A. Abstract.
39. Pettegrew JW, Minshew NJ, Payton JB. 31P NMR in normal IQ adult autistics. Biol Psychiatry. 1989;25(suppl):182A-183A. Abstract.
40. Rumsey JM, Duara R, Grady C, Rapoport JL, Margolin RA, Rapoport SI, Cutler NR. Brain metabolism in autism: resting cerebral glucose utilization rates as measured with positron emission tomography. Arch Gen Psychiatry. 1985;42:448-455.
41. Panchalingam K, Pettegrew JW, Strychor S, Tretta M. Effect of normal aging on membrane phospholipid metabolism by P in vivo NMR spectroscopy. Soc Neurosci. 1990;349:20. Abstract.
42. Morel BA. Traitement des maladies mentales. Paris, France: Victor Masson; 1860.
43. Andreasen N, Nasrallah HA, Dunn V, Olson SC, Grove WM, Ehrhardt JC, Coffman JA, Crossett JHW. Structural abnormalities in the frontal system in schizophrenia: a magnetic resonance imaging study. Arch Gen Psychiatry. 1986;43:136-144.
44. Andreasen NC. Brain imaging: applications in psychiatry. Science. 1988;239:1381-1388.
45. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med. 1990;322:789-794.
46. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res. 1982;17:319-334.
47. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987;44:660-669.
48. Huttenlocher PR, deCourten C, Garey LJ, Van Der Loos H. Synaptogenesis in human visual cortex: evidence for synapse elimination during normal development. Neurosci Lett. 1982;33:247-252.
49. Purves D, Lichtman JW. Elimination of synapses in the developing nervous system. Science. 1980;210:10:153-157.
50. Huttenlocher PR. Synaptic density in human frontal cortex: developmental changes and effects of aging. Brain Res. 1979;163:195-205.
51. Rakic P, Riley KP. Overproduction and elimination of retinal axons in the fetal rhesus monkey. Science. 1983;219:1441-1444.
52. Cowan WM, Fawcett JW, O'Leary DDM, Stanfield BB. Regressive events in neurogenesis. Science. 1984;225:1258-1265.
53. Falkai P, Bogerts B, Rozumek M. Cell loss and volume reduction in the entorhinal cortex of schizophrenics. Eur Arch Psychiatry Neurol Sci. 1988;24:515-521.
54. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtelotte WW. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science. 1984;225:728-731.
55. Jaskiw G, Kleinman J. Postmortem neurochemistry studies in schizophrenia. In: Schulz SC, Tamminga CA, eds. Schizophrenia: Scientific Progress. New York, NY: Oxford University Press; 1989:264-273.
56. Kornhuber J, Riederer P, Reynolds G.P, Beckmann H, Jellinger K, Gabriel E. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm. 1989;75:1-10.
57. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, Lorcan A, O'Tuama O, Snyder SH, Kuhar MJ, Gjedde A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics Science. 1986;234:1558-1563.
58. A correction appears in Science. 1987;235:623.
59. Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry. 1987;44:671-672.
60. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. In press.
61. Carruthers A, Helgerson AL, Herbert DN, Tefft RE Jr, Naderi S, Melchior DL. Effects of calcium, ATP and lipids on human erythrocyte sugar transport. Ann N Y Acad Sci. 1989;568:52-67.